Kentucky Bioprocessing LLC (KBP) and Bayer Innovation GmbH, a subsidiary of German pharmaceutical giant Bayer AG, are collaborating to develop a facility at KBP’s Owensboro plant for the production service of biopharmaceuticals. Based on Bayer’s proprietary magnICON® technology, plant-made pharmaceutical proteins and other high-value products will be produced in tobacco plants on commercial scale. KBP is investing $2 to $3 million to expand the partnership with Bayer and will adapt its existing facility for the installation of an automated system to accommodate production.
Owensboro
The Lane Report
- Greater Louisville March home sales down 5% from year ago
- School of Medicine, UofL Health create first-ever joint leadership role
- MSU Space Science programs expand reach and student opportunities
- New Ky Home initiative offers free marketing workshops to small business
- 18 UK faculty named 2025-26 University Research Professors
- Markey research team discovers gut hormone’s role in fatty liver disease
- OP-ED: State moving to speed up driver’s license system
- E & E Hardwoods to establish new operation in Bell County with $2.1M investment
- OpEd: Ky House leaders wisely insisted on 340B accountability
- Aegis Sortation to expand Louisville operation with nearly $16M investment
Add Comment